Does Mild Hemophilia Need Prophylaxis or On-Demand Therapy?
At a Glance
Most people with mild hemophilia use treatment when bleeding occurs, but regular preventive treatment may help those with frequent or severe bleeds, recurrent joint bleeding or damage, or selected high-risk activities. Surgery and dental work require advance planning with a specialist care team.
For most people with mild hemophilia, on-demand therapy—treatment given only when a bleed or injury occurs—is the standard approach. However, the need for prophylactic treatment (regular, preventative medication) is not a strict either/or choice and depends on your personal bleeding patterns and goals. While many people with mild hemophilia use on-demand treatment for routine bleeds, some may benefit from short-term perioperative coverage for procedures, or regular prophylaxis if their bleeding history justifies it [1].
Understanding Mild Hemophilia
Hemophilia severity is based on the percentage of clotting factor (Factor VIII for Hemophilia A, or Factor IX for Hemophilia B) in the blood. Mild hemophilia is defined as having a factor activity level between 5% and 40% of normal [1].
Many people with mild hemophilia bleed mainly after procedures or injury, but clinically important bleeding can also occur after dental work, heavy menstrual bleeding, childbirth, or minor trauma [1]. Additionally, your factor percentage does not perfectly predict how your body will respond. People with non-severe hemophilia can still experience a significant bleeding burden and progressive joint damage, and rarely, even spontaneous bleeds [1].
On-Demand Therapy vs. Prophylaxis
On-demand therapy means treating a bleed after it starts. For many people with mild hemophilia, this approach is sufficient. Treatments may include clotting factor concentrates or desmopressin (DDAVP) [2][3].
- Important DDAVP Safety Limits: DDAVP is only an option for some people with Hemophilia A (because it raises Factor VIII, not Factor IX) [4][5]. It should never be used to self-treat an unfamiliar bleed without a prior, documented test dose [6]. Because DDAVP causes the body to retain water, you must follow strict fluid restriction instructions from your team to avoid a dangerous drop in blood sodium (hyponatremia) [7]. Additionally, repeated doses over several days can lose their effectiveness [8].
Prophylaxis involves routine treatments to prevent bleeding before it starts. While traditionally reserved for severe hemophilia, prophylaxis can reduce bleeding in selected individuals with mild hemophilia [9][10]. Your hematologist might recommend it if you:
- Have frequent or severe bleeding episodes [1].
- Have recurrent joint bleeds (which can present as new pain, swelling, warmth, or reduced movement) or signs of joint damage [1][11].
- Participate in high-impact activities [1]. However, prophylaxis does not make collision sports entirely safe. Activity choice, protective equipment, and a pre-activity treatment plan must be individually assessed with your care team.
Managing High-Risk Situations
Even if you manage your condition with on-demand therapy, certain situations require proactive medical planning with your Hemophilia Treatment Center (HTC), a specialized comprehensive care team:
- Surgery and Dental Work: Never go into surgery or invasive dental procedures with a “wait and see” approach. Coordinate with your HTC ahead of time [12][13]. Your plan might include DDAVP, factor replacement, an antifibrinolytic medication like tranexamic acid (which prevents blood clots from breaking down), and/or local measures [14][12].
- Monitoring for Inhibitors: Any time you receive intensive factor replacement, your HTC should plan follow-up testing to monitor for inhibitors (antibodies developed by the immune system that stop the treatment from working). This risk is particularly relevant after intensive Factor VIII exposure in some people with mild hemophilia A [15].
When to Seek Urgent Help
Certain injuries require emergency evaluation and treatment before imaging is completed or symptoms become severe. Seek immediate emergency care and contact your HTC if you experience:
- Head, neck, throat, abdominal, or back trauma: Even if the injury seems minor initially, internal bleeding can be life-threatening [16][17].
- Signs of internal bleeding: Severe or persistent headache, vomiting, unusual sleepiness, weakness, abdominal distension or pain, black stools, or blood in your urine [17][18].
- Signs of deep muscle bleeding: Hip or groin pain accompanied by reduced hip movement or numbness/tingling in your leg can indicate a serious muscle bleed [19].
Daily Safety: Always carry a medical-alert identification and your HTC’s emergency contact information. Always consult your HTC before using pain relievers, as medications like aspirin or certain NSAIDs can increase bleeding risk.
Common questions in this guide
Do most people with mild hemophilia need prophylaxis every day?
What can make prophylaxis a better choice for mild hemophilia?
Is DDAVP safe for everyone with mild hemophilia?
How should I prepare for surgery or invasive dental work with mild hemophilia?
Which bleeding symptoms require emergency care?
What pain relievers are safe with mild hemophilia?
Related questions
Show more
Get notified when new evidence is published on Hemophilia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (19)
- 1
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature.
Iorio A, Königs C, Reding MT, et al.
Haemophilia : the official journal of the World Federation of Hemophilia 2023; (29(1)):33-44 doi:10.1111/hae.14676.
PMID: 36224704 - 2
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia.
Preijers T, Schütte LM, Kruip MJHA, et al.
Clinical pharmacokinetics 2021; (60(1)):1-16 doi:10.1007/s40262-020-00936-5.
PMID: 32936401 - 3
A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero?
Reardon B, Pasalic L, Favaloro EJ
Biomolecules 2025; (15(7)) doi:10.3390/biom15070967.
PMID: 40723839 - 4
Haemostasis and beyond: The expanding role of desmopressin in intensive care.
Vinjamuri S, Tiwari E, Kataria S, Juneja D
World journal of critical care medicine 2025; (14(4)):108370 doi:10.5492/wjccm.v14.i4.108370.
PMID: 41377554 - 5
Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B.
Preijers T, Schütte LM, Kruip MJHA, et al.
Therapeutic drug monitoring 2019; (41(2)):192-212 doi:10.1097/FTD.0000000000000625.
PMID: 30883513 - 6
Desmopressin (DDAVP): indications and practicalities.
Biguzzi E, Casini A, Bosch A, et al.
Swiss medical weekly 2026; (156()):5030 doi:10.57187/5030.
PMID: 42896092 - 7
Assessment and validation of a defined fluid restriction protocol in the use of subcutaneous desmopressin for children with inherited bleeding disorders.
Mason JA, Robertson JD, McCosker J, et al.
Haemophilia : the official journal of the World Federation of Hemophilia 2016; (22(5)):700-5 doi:10.1111/hae.12949.
PMID: 27385253 - 8
Tachyphylaxis and reproducibility of desmopressin response in perioperative persons with nonsevere hemophilia A: implications for clinical practice.
Romano LGR, Schütte LM, van Hest RM, et al.
Research and practice in thrombosis and haemostasis 2024; (8(3)):102367 doi:10.1016/j.rpth.2024.102367.
PMID: 38660455 - 9
Long-term analysis of the benefit of prophylaxis for adult patients with severe or moderate haemophilia A.
Miesbach W, Kittler S, Bauhofer A, et al.
Haemophilia : the official journal of the World Federation of Hemophilia 2020; (26(3)):467-477 doi:10.1111/hae.13988.
PMID: 32293085 - 10
Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.
Olasupo OO, Lowe MS, Krishan A, et al.
The Cochrane database of systematic reviews 2021; (8()):CD014201 doi:10.1002/14651858.CD014201.
PMID: 34407214 - 11
Ankle hemophilic arthropathy: literature review.
Greco T, Polichetti C, Cannella A, et al.
American journal of blood research 2021; (11(3)):206-216.
PMID: 34322283 - 12
Retrospective evaluation of multidisciplinary perioperative hemostatic management in oral surgery for patients with hemophilia.
Jung TY
Journal of the Korean Association of Oral and Maxillofacial Surgeons 2026; (52(5)):219-228 doi:10.5125/jkaoms.2026.52.5.219.
PMID: 42957417 - 13
Hemophilia management: Huge impact of a tiny difference.
Kloosterman F, Zwagemaker AF, Abdi A, et al.
Research and practice in thrombosis and haemostasis 2020; (4(3)):377-385 doi:10.1002/rth2.12314.
PMID: 32211572 - 14
Outpatient minor oral surgery in patients with hemophilia: A case series of 23 patients.
Ramos EA, Diamante M, Caruso D, et al.
Journal of clinical and experimental dentistry 2019; (11(4)):e395-e399 doi:10.4317/jced.55506.
PMID: 31110621 - 15
Parapharyngeal hematoma following transesophageal echo in a patient with hemophilia A.
McKenna D, Pampu T, Korda M, Benson G
Clinical case reports 2023; (11(6)):e7558 doi:10.1002/ccr3.7558.
PMID: 37323258 - 16
"Haemophilia A" - Presenting with oral squamous cell carcinoma diagnosis and management strategies.
K P A, Thakur S, Hanagvadi S, Siva Bharani KSN
Oral oncology 2022; (132()):105994 doi:10.1016/j.oraloncology.2022.105994.
PMID: 35785746 - 17
Spontaneous Hemopericardium Complicated by Tamponade in a Child With Moderate Hemophilia A: Case-Based Review.
Zayani S, Thabet F, Ben Massoud M, et al.
World journal for pediatric & congenital heart surgery 2023; (14(4)):518-520 doi:10.1177/21501351231168868.
PMID: 37128148 - 18
Splenic artery embolization for the treatment of spontaneous splenic rupture in hemophilia A: a case report.
He X, Zhang J
AME case reports 2025; (9()):113 doi:10.21037/acr-2025-141.
PMID: 41210426 - 19
Iliopsoas hematomas in people with hemophilia: diagnosis and treatment.
Rodriguez-Merchan EC, De la Corte-Rodriguez H
Expert review of hematology 2020; (13(8)):803-809 doi:10.1080/17474086.2020.1787146.
PMID: 32574080
This page is for informational purposes only and does not constitute medical advice. Your hematologist and Hemophilia Treatment Center should guide decisions about prophylaxis, on-demand treatment, and emergency care.